- o **Investment Rational**
  Immunai leverages multi-omic single cell analysis,functional genomics and computational methods to develop the next-generation of immunomodulatory therapeutics. Immunai's platform can be applied to most diseases, with a focus on cancer and autoimmunity. We built and expanded our platform over the past 3.5 years, secured notable partnerships with leading industry and academic collaborators, and expanded globally.

- o **Business Strategy**
  Immunai collaborates with leading biopharmaceutical companies and academic research institutions to identify and improve novel therapeutics and unlock biological insights. Typical projects include target discovery, early therapeutic development partnerships, biomarker discovery, and immune-driven exploration of patient selection for a therapeutic. These partnerships drive our data collection, IP strategy, as well as short- and long-term revenues through milestones and royalties.

- o **Core Technology**
  A fundamental component of our platform is AMICA - the world's largest cell-level immune database. AMICA drives our discovery & development work and facilitates transfer learning of immune insights. Immunai's platform enables novel insights that reveal actionable therapeutic targets and accelerates drug development.
  Immunai bridges causal immunology and translational disease biology. Multiomic single-cell readout guides pooled CRISPR perturbations in vitro. Molecular perturbations are mapped against multiomic profiling of our longitudinal patient cohorts, and vice versa, to generate novel, differentiated insights for discovery and development.

- o **Product Profile/Pipeline**
  We have dozens of strategic partnerships with academic research institutions and biopharmaceutical companies, working to discover and advance novel therapeutics and accelerate R&D. We have built proprietary knowledge libraries and deep expertise in a variety of immune cell compartments, including T cell and myeloid suppression. Our long-term vision is pan-immune, but we're focusing first on immuno-oncology and autoimmune diseases.

- o **What's Next?**
  Immunai's next key milestone is to co-develop preclinical candidates together with biotechnology and biopharma companies. As the platform has matured to enable the discovery and validation of candidates, Immunai's expand its capabilities to support data-driven clinical decision making, improved disease selection, combination strategy, and improved patient stratification and biomarkers.